Key facts
- Ascribe’s last known valuation is $48.0M (Oct 2025).
- It has raised $20.7M; the latest was Later Stage VC ($15.0M) in Oct 2025.
- Notable investors include Creative Destruction Lab, US National Science Foundation, National Institutes of Health, Cultivation Capital, The Yield Lab — 16 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 16 names
- ·Watchlist + deal alerts for Ascribe
- ·The full record, as it builds
Funding rounds
No funding rounds for Ascribe are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Ascribe
Developer of crop protection products designed to protect crops from pests, fungi and other small orgasms. The company's products are developed by researching the interaction of microbes and plants at the molecular level to identify the signaling molecules that activate a plant's natural immunity, enabling farmers to enhance the quality and productivity of crops.
- Sector
- Materials and Resources
- HQ
- Ithaca, NY, United States
- Founded
- 2017
- Employees
- 9
- Website
- ascribebio.com/
- Ownership
- Privately Held (backing)
Ascribe doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Ascribe shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Ascribe in its N-PORT filings yet. We sweep new filings monthly.